One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Caribou Biosciences, Inc.
CRBU · NMS · Healthcare · Biotechnology
Current price
$1.30
52-week range
$1.25 - $3.54
Market cap
$139.37M
Balance sheet
Healthy
-17,024.25x Concerning
Net cash $85.66M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Operating margin compressed from -768.2% to -1690.4% over 3 years.
- Risk Return on equity was -78.3% last year — the company lost money on shareholders' equity.
What this company does
Caribou Biosciences, Inc.
Caribou Biosciences is a healthcare company using gene-editing technology to develop new treatments for difficult-to-treat cancers. Because its potential medicines are still being tested in what's called the clinical stage, the company doesn't make money from sales yet. Its value is based on the hope that these therapies will eventually be approved and help patients in the future.
How the company got here
Caribou Biosciences was started in 2011 by pioneers in the field of gene editing, including Jennifer Doudna, who later won a Nobel Prize for her work on CRISPR technology. The company was founded to use this powerful gene-editing tool to create new medicines. A key moment was in 2021 when Caribou became a publicly traded company through an IPO (Initial Public Offering, when a private company first sells shares of stock to the public), which raised a significant amount of money to fund its research. Since then, it has focused on advancing its potential therapies through clinical trials (studies in humans to test a new drug's safety and effectiveness).
What it actually does
Caribou Biosciences is working on creating treatments for cancer and other serious diseases using a technology called CRISPR gene editing. Think of CRISPR as a tiny pair of molecular scissors that can precisely cut and change a cell's DNA. Caribou's special version, called chRDNA, is designed to be even more accurate. They use this technology to create "off-the-shelf" cell therapies, which means the treatments are made from the cells of healthy donors, not the patient's own, making them potentially faster and cheaper to produce.
Developing Gene-Edited Cell Therapies
The company operates as one main business: developing a pipeline (the set of products a company is developing) of potential medicines. It doesn't sell any products yet; instead, it spends money on research and clinical trials to prove its therapies work. Its main focus is on a type of treatment called CAR-T cell therapy, where immune cells are engineered to recognize and fight cancer. Because Caribou is a clinical-stage company, its value is based on the promise of its experimental drugs making it through the approval process and eventually being sold to patients.
What management is betting on now
The company's leadership is currently concentrating all its resources on its two most promising cancer treatments, known as CB-010 and CB-011. This decision is part of a strategic prioritization (a plan to focus on the most important projects) to make their money last longer, a concept known as extending their cash runway (the amount of time a company can operate before it runs out of money). By pausing other research and reducing staff, they are betting that these two therapies have the best chance of success in clinical trials. Their goal is to produce strong data that proves the treatments are effective and safe, which would be a major step toward getting them approved for patients.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-33.33M
FY2024 Q4
$-35.99M
FY2025 Q1
$-37.77M
FY2025 Q2
$-28.68M
FY2025 Q3
$-25.30M
FY2025 Q4
$-21.04M
FY2026 Q1
$-27.06M
FY2026 Q2
$-22.79M
Revenue
$1.50M
Net income
$-24.28M
Diluted EPS
-0.24
Operating cash flow
$-22.79M
Free cash flow
$-22.79M
Fetching…
Sources
Revenue
$2.40M
Net income
$-25.09M
Diluted EPS
-0.26
Operating cash flow
$-26.98M
Free cash flow
$-27.06M
Fetching…
Sources
Revenue
$3.94M
Net income
$-26.49M
Diluted EPS
-0.28
Operating cash flow
$-20.82M
Free cash flow
$-21.04M
Fetching…
Sources
Revenue
$2.20M
Net income
$-27.55M
Diluted EPS
-0.30
Operating cash flow
$-25.18M
Free cash flow
$-25.30M
Fetching…
Sources
Revenue
$2.67M
Net income
$-54.10M
Diluted EPS
-0.58
Operating cash flow
$-28.26M
Free cash flow
$-28.68M
Fetching…
Sources
Revenue
$2.35M
Net income
$-39.99M
Diluted EPS
-0.43
Operating cash flow
$-36.73M
Free cash flow
$-37.77M
Fetching…
Sources
Revenue
$2.08M
Net income
$-35.49M
Diluted EPS
-0.39
Operating cash flow
$-35.47M
Free cash flow
$-35.99M
Fetching…
Sources
Revenue
$2.02M
Net income
$-34.68M
Diluted EPS
-0.38
Operating cash flow
$-32.66M
Free cash flow
$-33.33M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.30
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $85.7M - more cash than debt. Interest coverage -17024.2x.
Net debt
$-85.66M
Interest coverage
-17,024.25x
Caribou Biosciences, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
CRBU
BASELINE
Caribou Biosciences, Inc.
Total debt $26.66M Interest coverage -17,024.25x This is the baseline the peer rows are being compared against.
Total debt $28.10M Interest coverage -36.67x Neither company has much profit cushion over interest right now.
Total debt $15.51M Interest coverage -16.10x Neither company has much profit cushion over interest right now.
Total debt $79.01M Interest coverage -192.50x Neither company has much profit cushion over interest right now.
What you should know
The case for and against CRBU
0 Rewards
2 Risks
Rewards
Risks
-
Operating margin compressed from -768.2% to -1690.4% over 3 years.
-
Return on equity was -78.3% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.03x
P/B
1.40x
P/S
13.89x
EV/EBITDA
-0.51x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
-1,690.4%
Net margin
0.0%
ROE
-78.3%
ROA
-36.8%
Health
Liquidity and balance-sheet strength
Debt / equity
0.27x
Current ratio
6.49x
Quick ratio
6.36x
Total debt
$26.66M
Total cash
$112.31M
Growth
How the business has been compounding
Revenue TTM
$10.04M
Revenue 5Y CAGR
3.8%
EPS TTM
-1.08
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-95.78M
Free CF TTM
$-112.35M
FCF margin
-1,119.6%
Dividend
Shareholder payout
Yield
—
Payout ratio
0.0%
Last ex-div date
—